Kadimastem Ltd

Tel Aviv Stock Exchange KDST.TA

Kadimastem Ltd Capital Expenditure for the year ending December 31, 2023: USD -6.33 K

Kadimastem Ltd Capital Expenditure is USD -6.33 K for the year ending December 31, 2023, a 96.52% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Kadimastem Ltd Capital Expenditure for the year ending December 31, 2022 was USD -181.87 K, a -5.43% change year over year.
Kadimastem Ltd Capital Expenditure for the year ending December 31, 2021 was USD -172.50 K, a -246.63% change year over year.
Kadimastem Ltd Capital Expenditure for the year ending December 31, 2020 was USD -49.76 K, a 76.67% change year over year.
Kadimastem Ltd Capital Expenditure for the year ending December 31, 2019 was USD -213.31 K, a -0.82% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Tel Aviv Stock Exchange: KDST.TA

Kadimastem Ltd

CEO	Mr. Ronen Twito CPA
IPO Date	June 13, 2013
Location	Israel
Headquarters	Pinchas Sapir 7
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

Key trends

Past 5 years